Physician profile
Robert Loeb
NPI 1730110966
$1,565.16
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.62 · 2021: $93.72 · 2022: $565 · 2023: $203 · 2024: $500 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745 · Entertainment: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.11 |
| Entertainment | $110.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $293.91 | 2024-2025 | Xdemvy |
| Abbvie INC. | $283.44 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $268.67 | 2022-2024 | Cequa |
| Rxsight INC | $190.11 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $182.36 | 2022-2024 | |
| Optos, INC. | $110.29 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $61.08 | 2019-2024 | Rocklatan |
| Horizon Therapeutics Plc | $49.17 | 2021-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $40.60 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $23.83 | 2021 | |
| Bausch & Lomb Americas INC. | $22.60 | 2023 | Vyzulta |
| Thea Pharma INC. | $20.97 | 2022 | |
| Allergan, INC. | $18.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Loeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.